Sign In
Buy MRNA
$49.06
+3.42 (+7.49%)
At Close: Jun 03, 2026
Moderna CMO Jacqueline Miller to step down
09:06am, Friday, 30'th Jan 2026
Moderna's Chief Medical Officer Jacqueline Miller, who led the development of the company's mRNA-based COVID-19 vaccine Spikevax, will step down effective March 2, the vaccine maker said on Friday.
Dr. David Berman to Join Moderna as Chief Development Officer
07:30am, Friday, 30'th Jan 2026
CAMBRIDGE, MASSACHUSETTS / ACCESS Newswire / January 30, 2026 / Moderna, Inc. (NASDAQ:MRNA) today announced that David Berman, M.D., Ph.D. has been appointed as the Company's Chief Development Officer
mRNA-3927 is a strong strategic fit with Recordati's rare Metabolic portfolio Collaboration combines Moderna's expertise in mRNA technology for rare metabolic disorders with Recordati's established gl
Moderna will continue to lead clinical development and manufacturing for mRNA-3927 Moderna to receive up to $160 million in upfront and near-term development and regulatory milestones, in addition to
Moderna, Inc. $MRNA Shares Sold by Federated Hermes Inc.
04:26am, Thursday, 29'th Jan 2026
Federated Hermes Inc. decreased its stake in shares of Moderna, Inc. (NASDAQ: MRNA) by 3.1% during the third quarter, according to the company in its most recent disclosure with the SEC. The instituti
This Stock Is Already Up 58% This Year. Is It a Buy?
08:45pm, Wednesday, 28'th Jan 2026
One of Moderna's leading drug candidates is proving highly effective in clinical trials. It could help expand Moderna's lineup and boost its financial results.
Moderna (MRNA) Stock Falls Amid Market Uptick: What Investors Need to Know
06:50pm, Monday, 26'th Jan 2026
Moderna (MRNA) closed the most recent trading day at $47.99, moving 1.48% from the previous trading session.
Moderna to Report Fourth Quarter 2025 Financial Results on Friday, February 13, 2026
07:00am, Monday, 26'th Jan 2026
CAMBRIDGE, MA / ACCESS Newswire / January 26, 2026 / Moderna, Inc. (NASDAQ:MRNA), today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Friday, February 13, 2026 to r
Last week's top large-cap gainers were led by precious-metals names and included standout moves in Venture Global, Moderna, Micron and Korea Electric.
MRNY: Jumping On Big Moderna Move
10:09pm, Thursday, 22'nd Jan 2026
YieldMax MRNA Option Income Strategy ETF has rebounded sharply from historic lows, driven by positive catalysts in underlying Moderna. MRNY's distributions have increased alongside MRNA's share price
Baseline characteristics in Moderna cancer vaccine 'misleading': Leerink's Dr. Mani Foroohar
05:22pm, Thursday, 22'nd Jan 2026
Dr. Mani Foroohar, Leerink Partners, joins 'Closing Bell Overtime' to talk Moderna prices climbing on positive drug trial.
MRNA & MRK's Personalized Cancer Therapy Delivers Strong 5-Year Data
12:40pm, Thursday, 22'nd Jan 2026
Moderna rises after five-year phase IIb data show the combo of intismeran autogene plus Keytruda cuts recurrence or death risk by 49% in high-risk melanoma.
Moderna is curbing investment in vaccine trials due to US backlash
11:20am, Thursday, 22'nd Jan 2026
Moderna CEO Stephane Bancel said the company doesn't plan to invest in new late-stage vaccine trials because of growing opposition to immunizations from US officials https://bloom.bg/3LNHufg
Moderna curbing investments in vaccine trials due to US backlash, CEO tells Bloomberg TV
11:08am, Thursday, 22'nd Jan 2026
Moderna does not plan to invest in new late-stage vaccine trials because of growing opposition to immunizations from U.S. officials, CEO Stephane Bancel said in an interview with Bloomberg TV on Thurs
Moderna CEO Says Vaccine Scrutiny Is Curbing Trials
10:08am, Thursday, 22'nd Jan 2026
Moderna CEO Stephane Bancel says the company does not plan to invest in late-stage vaccine trials because of growing scrutiny of immunizations from US officials. He speaks with Lisa Abramowicz at the
